Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure

Research output: Contribution to journal › Journal article › Research › peer-review

We tested the hypothesis that moderate increases in endogenous angiotensin II (Ang II) concentrations, induced by withdrawal of angiotensin converting enzyme inhibition (ACE-I) in patients with compensated heart failure (HF) on chronic medical therapy, do not increase or impair control of systemic vascular resistance (SVR). SVR was determined in supine and seated positions in 12 HF patients [NYHA class II-III; ejection fraction=0.29 +/- 0.03 (mean +/- SE)] and 9 control subjects. HF patients were investigated during high (n=11; withdrawal of ACE-I treatment for 24 h) and low (n=9; sustained ACE-I therapy) endogenous plasma Ang II concentrations. Withdrawal of ACE-I therapy in HF caused moderately increased Ang II concentrations of 30 +/- 5 pg/ml compared with 12 +/- 2 pg/ml in controls (p
Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Volume62
Issue number4
Pages (from-to)245-54
Number of pages10
ISSN0036-5513
Publication statusPublished - 1 Jan 2002

    Research areas

  • Angiotensin-Converting Enzyme Inhibitors, Baroreflex, Blood Pressure, Cardiac Output, Heart Failure, Humans, Male, Middle Aged, Posture, Substance Withdrawal Syndrome, Sympathetic Nervous System, Vascular Resistance

ID: 33967768